RxDoctor Payments Data

Srinivas Yallapragada

Interventional Cardiology · Dallas, TXNPI 1174752372

Payments from drug & device makers

$222,653in general payments, 2019–2025

Across 685 payments — averaging $325.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Imperative Care, Inc$93K
  • Inari Medical, Inc.$75K
  • Stryker$13K
  • Penumbra, Inc.$12K
  • Bard Peripheral Vascular, Inc.$7K
  • Medtronic$6K
  • plus $16K from 41 others
$2,000in research payments, 2019–2025

Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$2K

What the payments were for

  • Consulting fees$10,40010%
  • Speaking & faculty fees$52,59653%
  • Travel & lodging$10,79011%
  • Food & beverage$25,24925%
  • Education$1140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$222,653 in reported general payments places this provider in the 90th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$194,666
Medicare patients
553
Services billed
1,929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban203$226,338
XareltoRivaroxaban59$62,590
BrilintaTicagrelor34$31,210
EntrestoSacubitril/Valsartan25$27,838
FarxigaDapagliflozin Propanediol13$21,456
Repatha SureclickEvolocumab11$15,330
Ranolazine ErRanolazine47$6,270
Nifedipine ErNifedipine94$3,987
Carvedilol418$3,752
Metoprolol Succinate325$3,495
Atorvastatin Calcium385$3,413
ClopidogrelClopidogrel Bisulfate304$2,745
Bumetanide69$2,265
Losartan Potassium258$2,013
Valsartan55$1,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$511$226,338203 claims
Johnson & JohnsonXarelto$118$62,59059 claims
AstraZenecaBrilinta, Farxiga$244$52,66647 claims
NovartisEntresto$822$27,83825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →